NZ591312A - Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct - Google Patents

Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct

Info

Publication number
NZ591312A
NZ591312A NZ591312A NZ59131209A NZ591312A NZ 591312 A NZ591312 A NZ 591312A NZ 591312 A NZ591312 A NZ 591312A NZ 59131209 A NZ59131209 A NZ 59131209A NZ 591312 A NZ591312 A NZ 591312A
Authority
NZ
New Zealand
Prior art keywords
treatment
single chain
chain antibody
lymphoblastic leukemia
acute lymphoblastic
Prior art date
Application number
NZ591312A
Other languages
English (en)
Inventor
Gerhard Zugmaier
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NZ591312A publication Critical patent/NZ591312A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ591312A 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct NZ591312A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
US22126909P 2009-06-29 2009-06-29
PCT/EP2009/007969 WO2010052013A1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
NZ591312A true NZ591312A (en) 2012-09-28

Family

ID=41796119

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591312A NZ591312A (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct

Country Status (27)

Country Link
US (2) US20110262440A1 (enExample)
EP (4) EP2344539B1 (enExample)
JP (2) JP5798036B2 (enExample)
KR (1) KR101695329B1 (enExample)
CN (2) CN102209729B (enExample)
AU (1) AU2009313039B2 (enExample)
BR (1) BRPI0921341A2 (enExample)
CA (1) CA2742242C (enExample)
CY (3) CY1116160T1 (enExample)
DK (3) DK2918604T3 (enExample)
ES (3) ES2748126T3 (enExample)
HK (1) HK1255590B (enExample)
HR (3) HRP20150400T1 (enExample)
HU (3) HUE025452T2 (enExample)
IL (1) IL212651A (enExample)
LT (2) LT2918604T (enExample)
MX (1) MX2011002931A (enExample)
NO (1) NO2918604T3 (enExample)
NZ (1) NZ591312A (enExample)
PL (3) PL2918604T3 (enExample)
PT (3) PT2344539E (enExample)
RS (3) RS53980B1 (enExample)
RU (3) RU2536933C2 (enExample)
SG (1) SG195549A1 (enExample)
SI (3) SI2344539T1 (enExample)
SM (3) SMT201800149T1 (enExample)
WO (1) WO2010052013A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
RS53980B1 (sr) * 2008-11-07 2015-10-30 Amgen Research (Munich) Gmbh Tretiranje akutne limfoblastne leukemije kod dece
ES2565439T3 (es) * 2009-01-09 2016-04-04 Oxford Biomedica (Uk) Ltd Factores
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HK1209434A1 (en) * 2012-11-13 2016-04-01 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
LT3149480T (lt) 2014-05-30 2019-04-25 Amgen Research (Munich) Gmbh B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas
EP3175001B1 (en) 2014-07-30 2021-02-10 Mor Research Applications Ltd. Prognostic methods and systems of treatment for acute lymphoblastic leukemia
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
AU2016215110A1 (en) * 2015-02-05 2017-09-21 Stc.Unm Anti-pre-BCR antagonists and methods
PL3277725T3 (pl) 2015-03-30 2021-06-14 Regeneron Pharmaceuticals, Inc. Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma
PT3280729T (pt) 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
DK3298042T3 (da) * 2015-05-20 2025-02-24 Amgen Res Munich Gmbh B-celledepletering som en diagnostisk markør
KR20180087401A (ko) * 2015-12-22 2018-08-01 리제너론 파아마슈티컬스, 인크. 급성 림프아구성 백혈병을 치료하기 위한 이중특이성 항-cd20/항-cd3 항체
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
BR112018068628A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc método de prevenção de doença do enxerto contra hospedeiro
MA45341A (fr) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
UY37726A (es) * 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
MX2019014268A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
LT3844189T (lt) 2018-08-31 2025-02-25 Regeneron Pharmaceuticals, Inc. Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą
BR112021014255A2 (pt) * 2019-01-30 2022-01-18 Wistar Inst Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
IL305188A (en) 2021-02-16 2023-10-01 Childrens Health Care D/B/A Childrens Minnesota Methods for treating B-ALL by administering a pre-BCR complex antagonist
WO2023062188A1 (en) 2021-10-15 2023-04-20 Amgen Research (Munich) Gmbh Subcutaneous administration of cd19-binding t cell engaging antibodies
US20250146017A1 (en) 2023-11-06 2025-05-08 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008875A1 (de) * 1996-08-28 1998-03-05 Viva Diagnostika Diagnostische Produkte Gmbh Kombinationspräparationen und ihre verwendung in der immundiagnostik und immuntherapie
JP4169478B2 (ja) * 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
PT1976886E (pt) 2005-12-16 2015-03-09 Amgen Res Munich Gmbh Meios e processos para o tratamento de doenças tumorais
ES2402591T3 (es) * 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
ES2582603T5 (es) * 2008-10-01 2022-12-02 Amgen Res Munich Gmbh Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular
RS53980B1 (sr) * 2008-11-07 2015-10-30 Amgen Research (Munich) Gmbh Tretiranje akutne limfoblastne leukemije kod dece
PL2511264T3 (pl) * 2009-01-19 2015-08-31 Abbvie Inc Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
AU2010204555B2 (en) * 2009-01-19 2013-03-07 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102459236B (zh) * 2009-05-27 2014-10-29 Abbvie公司 激酶活性的嘧啶抑制剂
CA2771984A1 (en) * 2009-09-20 2011-03-24 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
US8840888B2 (en) * 2009-10-27 2014-09-23 Micromet Ag Dosage regimen for administering a CD19XCD3 bispecific antibody

Also Published As

Publication number Publication date
SMT201500104B (it) 2015-07-09
RU2018144313A3 (enExample) 2020-06-15
KR101695329B1 (ko) 2017-01-23
BRPI0921341A2 (pt) 2016-04-26
LT3330293T (lt) 2019-10-10
CN102209729B (zh) 2016-05-25
HK1158667A1 (en) 2012-07-20
RS53980B1 (sr) 2015-10-30
CN102209729A (zh) 2011-10-05
CY1122428T1 (el) 2021-01-27
JP5798036B2 (ja) 2015-10-21
EP3594237A1 (en) 2020-01-15
US20230235053A1 (en) 2023-07-27
PL2344539T3 (pl) 2015-07-31
HK1215258A1 (en) 2016-08-19
DK2344539T3 (en) 2015-05-04
PT2918604T (pt) 2018-03-02
ES2535257T3 (es) 2015-05-07
RS59348B1 (sr) 2019-10-31
SMT201800149T1 (it) 2018-05-02
HUE025452T2 (en) 2016-05-30
HRP20180426T1 (hr) 2018-04-20
RU2014141180A3 (enExample) 2018-06-09
EP2918604B1 (en) 2017-12-20
SMT201900546T1 (it) 2019-11-13
SI2918604T1 (en) 2018-04-30
ES2662929T3 (es) 2018-04-10
AU2009313039A1 (en) 2010-05-14
PL2918604T3 (pl) 2018-05-30
WO2010052013A1 (en) 2010-05-14
RU2018144313A (ru) 2020-06-15
IL212651A (en) 2015-03-31
HRP20191715T1 (hr) 2019-12-13
CY1116160T1 (el) 2017-02-08
KR20110091669A (ko) 2011-08-12
HRP20150400T1 (hr) 2015-05-08
US20110262440A1 (en) 2011-10-27
CN106390114A (zh) 2017-02-15
HUE046222T2 (hu) 2020-02-28
RS56989B1 (sr) 2018-05-31
RU2536933C2 (ru) 2014-12-27
DK3330293T3 (da) 2019-10-07
PT3330293T (pt) 2019-10-18
CA2742242C (en) 2023-01-10
CA2742242A1 (en) 2010-05-14
HK1255590B (en) 2020-07-10
RU2736802C2 (ru) 2020-11-20
CY1120022T1 (el) 2018-12-12
RU2677324C2 (ru) 2019-01-16
LT2918604T (lt) 2018-03-26
SI2344539T1 (sl) 2015-06-30
EP3330293B1 (en) 2019-07-24
MX2011002931A (es) 2011-04-11
PL3330293T3 (pl) 2020-02-28
PT2344539E (pt) 2015-04-01
HUE036922T2 (hu) 2018-08-28
EP2344539A1 (en) 2011-07-20
ES2748126T3 (es) 2020-03-13
IL212651A0 (en) 2011-07-31
SG195549A1 (en) 2013-12-30
RU2014141180A (ru) 2016-05-10
JP2012508163A (ja) 2012-04-05
AU2009313039B2 (en) 2015-06-18
EP2918604A1 (en) 2015-09-16
DK2918604T3 (en) 2018-03-19
NO2918604T3 (enExample) 2018-05-19
SI3330293T1 (sl) 2019-10-30
EP3330293A1 (en) 2018-06-06
JP2015232023A (ja) 2015-12-24
RU2011122827A (ru) 2012-12-20
JP6130451B2 (ja) 2017-05-17
EP2344539B1 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
NZ591312A (en) Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
NZ591311A (en) Treatment of acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
TW200640488A (en) Extending time to disease progression or survival in cancer patients
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
IL201479A (en) Use of tapentadol for the preparation of pain medication
CL2007002667A1 (es) Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
MX2010006823A (es) Metodos para el tratamiento de la gota.
MY153408A (en) Novel methods
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
EA200970816A1 (ru) Новая лекарственная форма
UA29556U (ru) Способ лечения больных острыми вирусными менингитами
TW200738229A (en) Memantine for the normalization of visual acuity deficits
UA40843U (ru) Процесс лечения острого травматического повреждения легких
UA37170U (ru) Способ профилактики и лечения тканевой гипоксии при резервировании аутокрови
UA10952U (uk) Спосіб корекції розкладів мікроциркуляції та гемостазу у хворих на хронічний стеатогепатит із синдромом інсулінорезистентності
UA35021U (ru) Способ медицинской реабилитации больных неалкогольным стеатогепатитом
UA42783U (ru) Способ лечения дисбактериоза
LT2004047A (en) A stomach band
UA48015U (ru) Способ улучшения результатов лечения больных с повторной легкой черепно-мозговой травмой с использованием принципа "дорожной карты"
HK1153406A (en) Piperlongumine and piperlongumine analogs for use in the treatment of cancer
UA37950U (ru) Способ хирургического лечения глоссоптоза у детей с секвенцией пьера робина
UA39741U (uk) Спосіб проведення дренажу після операції на щитовидній залозі

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 NOV 2016 BY DENNEMEYER SA

Effective date: 20131017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2017 BY CPA GLOBAL

Effective date: 20160930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2018 BY CPA GLOBAL

Effective date: 20171005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2019 BY CPA GLOBAL

Effective date: 20181004

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2020 BY CPA GLOBAL

Effective date: 20191003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2021 BY CPA GLOBAL

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2022 BY CPA GLOBAL

Effective date: 20210930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2023 BY ANAQUA SERVICES

Effective date: 20221022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2025 BY ANAQUA SERVICES

Effective date: 20241022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2026 BY ANAQUA SERVICES

Effective date: 20251022